Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 1;13(11):1823.
doi: 10.3390/pharmaceutics13111823.

Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?

Leontina Elena Filipiuc  1   2 , Daniela Carmen Ababei  3 , Teodora Alexa-Stratulat  1   4 , Cosmin Vasilica Pricope  1   2 , Veronica Bild  1   3 , Raluca Stefanescu  1 , Gabriela Dumitrita Stanciu  1 , Bogdan-Ionel Tamba  1   2
Affiliations
Review

Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?

Leontina Elena Filipiuc et al. Pharmaceutics. .

Abstract

The most important discoveries in pharmacology, such as certain classes of analgesics or chemotherapeutics, started from natural extracts which have been found to have effects in traditional medicine. Cannabis, traditionally used in Asia for the treatment of pain, nausea, spasms, sleep, depression, and low appetite, is still a good candidate for the development of new compounds. If initially all attention was directed to the endocannabinoid system, recent studies suggest that many of the clinically proven effects are based on an intrinsic chain of mechanisms that do not necessarily involve only cannabinoid receptors. Recent research has shown that major phytocannabinoids and their derivatives also interact with non-cannabinoid receptors such as vanilloid receptor 1, transient receptor ankyrin 1 potential, peroxisome proliferator-activated receptor-gamma or glitazone receptor, G55 protein-coupled receptor, and nuclear receptor, producing pharmacological effects in diseases such as Alzheimer's, epilepsy, depression, neuropathic pain, cancer, and diabetes. Nonetheless, further studies are needed to elucidate the precise mechanisms of these compounds. Structure modulation of phytocannabinoids, in order to improve pharmacological effects, should not be limited to the exploration of cannabinoid receptors, and it should target other courses of action discovered through recent research.

Keywords: cannabidiol; cannabigerol; cannabinoid receptors; endocannabinoid system; pharmacology; phytocannabinoids; synthetic cannabinoids; tetrahydrocannabinol.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
Chemical structures and binding affinities of ten major phytocannabinoids able to cause, in vitro, the displacement of synthetic [3H]CP55940 bound to human cannabinoid receptors 1 or 2 both embedded in cellular membranes. The binding affinities are reported according to the published data available in the following scientific articles: a [65]; b [70]; c [68].The chemical structures were prepared with ACD/ChemSketch, and the three classes of phytocannabinoids are included in separate inserts. The substituents of the resorcinyl moiety whose replacements cause a change in affinity constants (Ki) are highlighted.
Figure 2
Figure 2
Chemical structures of CBG derivatives VCE-003 and VCE-003.2.
Figure 3
Figure 3
Chemical structure of CBDA derivative HU-580.
See this image and copyright information in PMC

References

    1. Abel E.L., Emboden W. Marihuana: The First Twelve Thousand Years. Q Rev. Biol. 1981;56:514.
    1. Tamba B.I., Stanciu G.D., Urîtu C.M., Rezus E., Stefanescu R., Mihai C.T., Luca A., Rusu-zota G., Leon-constantin M.M., Cojocaru E., et al. Challenges and Opportunities in Preclinical Research of Synthetic Cannabinoids for Pain Therapy. Medicina. 2020;56:24. doi: 10.3390/medicina56010024. - DOI - PMC - PubMed
    1. Turgeman I., Bar-Sela G. Cannabis for cancer–illusion or the tip of an iceberg: A review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology. Expert Opin. Investig. Drugs. 2019;28:285–296. doi: 10.1080/13543784.2019.1561859. - DOI - PubMed
    1. Zuardi A.W. History of cannabis as a medicine: A review. Rev. Bras. Psiquiatr. 2006;28:153–157. doi: 10.1590/S1516-44462006000200015. - DOI - PubMed
    1. Farag S., Kayser O. Handbook of Cannabis and Related Pathologies: Biology, Pharmacology, Diagnosis, and Treatment. Elsevier Inc.; Amsterdam, The Netherlands: 2017. The Cannabis Plant: Botanical Aspects; pp. 3–12.

LinkOut - more resources